PEOPLE ON THE MOVE
Advaxis
Immuno-oncology company Advaxis has announced the appointment of Shelonitda Rose as Vice President of Clinical Development. She will report to Chief Medical Officer, David Mauro, and oversee clinical development programmes for the company’s Lm Technology platform.
Advaxis has three clinical trials planned for 2015, including a study involving ADXS-PSA and Merck’s PD-1 checkpoint inhibitor Keytruda (pembrolizumab). The company also has immunotherapy candidates for cervical cancer, HPV-associated anal cancer and HER2-expressing solid tumours.
Rose joins the company from Merck & Co., where she was Director or Oncology Clinical Research and the medical monitor for Keytruda trials. She was also directed the Haematology-Oncology Fellowship Programme at the University of Medicine and Dentistry of New Jersey.
